Duloxetine and Neurofeedback Training for the Treatment of Chemotherapy Induced Peripheral Neuropathy
- Patients must have the ability to understand and read English, sign a written informed consent, and be willing to follow protocol requirements
- Eastern Cooperative Oncology Group (ECOG) performance status of 0-2
- Pain score >= 4 on a 0-10 numeric pain scale and/or grade 1-4 neuropathic pain according to the National Cancer Institute’s 4 point grading scale
- Neuropathic symptoms must be related to chemotherapy (in the opinion of the treating physician)
- Patients must have had neuropathic symptoms for a minimum of 3 months
- No plans to change pain medication regimen during the course of the study
- Off active chemotherapy treatment for minimum of 3 months
- Hormonal (e.g., tamoxifen or Arimidex, etc.) and targeted (Tarceva and Avastin, etc.) therapies allowed as long as they will be continued during the course of the study
- Willing to come to one of the participating cancer centers for the therapy sessions; or willing to participate in the therapy sessions at their homes and live within a 45 minute drive of the main campuses; or can participate in the therapy sessions from MD Anderson regional care centers
- If participants agree to the Remote Training Option, participants should be willing to receive equipment at their homes and to return the equipment to MDA in case of malfunction or completion of the study
- If participants agree to the Remote Training Option, participants should be willing to download necessary software to their home computer
- If participants agree to the Remote Training Option, participants should be willing to allow research staff remote access to their computer to run the neurofeedback program
- Patients who are taking any antipsychotic medications
- Patients with active central nervous system (CNS) disease, such as clinically-evident metastases or leptomeningeal disease, dementia, or encephalopathy
- Patients who have ever been diagnosed with bipolar disorder or schizophrenia
- Patients with known, previously diagnosed peripheral neuropathy from causes other than chemotherapy
- Patients who have a history of head injury or who have known seizure activity
- Patients for whom any contraindications of DL are known
- Patients with suicidal ideation
- Patients who are already taking duloxetine for peripheral neuropathy
I. Determine if the combination of duloxetine (DL) and neurofeedback (NFB) is superior to DL or NFB alone in treating chemotherapy induced peripheral neuropathy (CIPN).
I. Determine the optimal number of neurofeedback sessions needed to result in long-term relief of CIPN in a large cohort of cancer survivors and across socioeconomic groups.
II. Examine baseline brain signatures as a predictor of response to neurofeedback (NFB) and to duloxetine and determine who will require more sessions of NFB to achieve relief of symptoms.
III. Examine if the combination of DL + NFB (than those getting DL or NFB alone) or a larger number of NFB sessions results in better improvements in cancer-related symptoms, physical functioning, and quality of life (QOL).
OUTLINE: Patients are randomized to 1 of 3 groups.
GROUP I: Patients receive neurofeedback training over 1 hour each 3-5 times weekly for up to 5 weeks. Patients also receive duloxetine orally (PO) once daily (QD) for 5 weeks in the absence of unacceptable toxicity.
GROUP II: Patients receive neurofeedback training session over 1 hour 3-5 times weekly for up to 5 weeks.
GROUP III: Patients receive duloxetine PO QD for 5 weeks in the absence of unacceptable toxicity.
After completion of study, patients are followed up at 6 and 12 months.
Trial Phase Phase II
Trial Type Supportive care
M D Anderson Cancer Center
- Primary ID 2019-0712
- Secondary IDs NCI-2020-06553
- Clinicaltrials.gov ID NCT04560673